


Remarks

Applicants traverse this Restriction Requirement because it creates an excessive and unnecessary number of subgroups (15) that are very similar. The Office Action states that the compounds in the Markish group in Claim 1 do not share a common special technical feature. It is respectfully submitted that because the compounds are structurally similar enough to be defined by a Markush formula, and because the compounds are all useful for the treatment of chemokine receptor modulated diseases, the compounds share a special technical feature.

Applicants respectfully submit that a more reasonable group for purposes of restriction would be based on the combination of Groups IV, IX, X, and XII of the Office Action, where W and R¹ are connected to form a 5-membered ring, optionally having one double bond, Z in the left hand ring is C, N or O, n is 0-4, and m is 1-4. There are a limited number of choices for the left hand heterocyclic ring, which is always connected to the remainder of the molecule through a N atom and a tether group. This should be readily searchable, and eliminates the need for such a large number of patent applications. Such a restriction would not be traversed.

If the Examiner wishes to discuss this response, he is invited to telephone the undersigned attorney at the number below.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: December 17, 2007